NRx Pharmaceuticals secures $8.9M financing from Anson Funds to support NDA filings, operations into 2026

NRX Pharmaceuticals, Inc.

Issued $5.435M senior secured notes (net proceeds ~$5M) and warrants for 862,699 shares at $3.78 strike; registered direct offering of 1,215,278 shares at $2.88/share.
Total gross proceeds of ~$8.9M from Anson Funds; notes carry 8% OID, 6% interest, 15-month maturity, convertible at $3.78/share subject to reset.
Proceeds will fund NRX-100 and NRX-101 NDA filings, HOPE Therapeutics launch, and potential pipeline additions; expected to fund operations into 2026.
Company believes combined with projected sales and non-dilutive funding it can reach profitability; includes waiver of certain investor rights through March 31, 2025.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.